Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience

Pasello, Giulia; Nicotra, Samuele; Marulli, Giuseppe; Rea, Federico; Bonanno, Laura; Carli, Paolo; Magro, Cristina; Jirillo, Antonio; Favaretto, Adolfo

doi:10.1016/j.lungcan.2011.01.005

Cited by 10 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once again an interesting response was obtained, with a clinical benefit observed in 20 out of 30 patients (disease control rate, DCR, 66%, PR and SD), both by radiological assessment and reduction of pain. Overall TTP and survival were promising for a second-line setting of patients with advanced mesothelioma, 5.1 and 13.6 months, respectively, considering other similar reports from the literature: a French cohort, where several different drugs were used in second-line for patients affected by mesothelioma, showed 3.8 and 12.2 months, respectively for TTP and OS [21], while in a mono-institutional Italian cohort salvage therapy with gemcitabine-platin combination in second or further line demonstrated 3 and 5.5 months, respectively as TTP and OS [22]. We are aware that our group of patients was selected for good prognostic factors, such as PS, benefit after first-line treatment (SD or RP) and a quite long TTP after the end of first-line treatment; moreover no patient was affected by pure sarcomatoid histotype, considered one of the worst prognostic factors [23,24].…”

Section: Discussionmentioning

confidence: 58%

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience

et al. 2012

Self Cite

View full text Add to dashboard Cite

BackgroundAlthough first-line therapy for patients affected by advanced mesothelioma is well established, there is a lack of data regarding the impact of second-line treatment.MethodsWe retrospectively collected data of patients affected by advanced mesothelioma, already treated with first-line therapy based on pemetrexed and platin, with a response (partial response or stable disease) lasting at least 6 months, and re-treated with a pemetrexed-based therapy at progression. The primary objective was to describe time to progression and overall survival after re-treatment.ResultsOverall across several Italian oncological Institutions we found 30 patients affected by advanced mesothelioma, in progression after a 6-month lasting clinical benefit following a first-line treatment with cisplatin and pemetrexed, and re-challenged with a pemetrexed-based therapy. In these patients we found a disease control rate of 66%, with reduction of pain in 43% of patients. Overall time to progression and survival were promising for a second-line setting of patients with advanced mesothelioma, being 5.1 and 13.6 months, respectively.ConclusionsIn our opinion, when a patient has a long-lasting benefit from previous treatment with pemetrexed combined with a platin compound, the same treatment should be offered at progression.

show abstract

Section: Discussionmentioning

confidence: 58%

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since 2003, when antifolate agents were introduced in the clinical management of this disease, the standard procedure chemotherapy is a platinum-based doublet plus pemetrexed or raltitrexed. [30][31][32][33] Recent studies tested biologic agents that target key oncogenic pathways, including phosphatidylinositol3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways, histone deacetylases, nuclear factor kB, and neoangiogenesis. 29 After the standard first-line pemetrexed/platinum combination, there is not a defined regimen for the secondline treatment of MPM, and the clinical benefits are uncertain.…”

Section: Discussionmentioning

confidence: 99%

Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma

Pasello

Urso

Silic-Benussi

et al. 2014

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a study evaluated pemetrexed naïve patients with MPM, the median OS were 9.8 months and 8.6 months for pemetrexed and carboplatin (Sorensen et al, 2007). Generally, in most of studies, chemotherapy was able to control symptoms and prolong the time to progression (Agatsuma et al, 2010;Margery et al, 2010;Pasello et al, 2011;Tourkantonis et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Secondline Chemotherapy Versus Best Supportive Care in Patient with Malignant Pleural Mesothelioma: A Retrospective Study

Mutlu

Büyükçelik²,

Karaca³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Introduction: Mesothelioma is a rare neoplasm arising from mesothelial surfaces with the malignant pleural mesothelioma (MPM) as the most common form. Secondline chemotherapy in MPM is still controversial and in this study we evaluated whether it is superior to best supportive care. Materials and Methods: A total of 51 patients with MPM from Acibadem Kayseri Hospital, Kayseri Training and Research Hospital and Erciyes University were analyzed retrospectively. The patients treated with secondline chemotherapies (SLCT) were compared with those treated with best supportive care (BSC) for overall survival. Results: The median overall survival (OS) for firstline chemotherapygSLCT and firstline chemotherapygBSC groups were 20.3 and 14.7 months respectively (p=0.079). After firstline chemotherapy the median OS for SLCT and BSC were 5.9 and 4.7 months (p=0.355). Discussion: Although there was a trend for improvement in overall survival in patients treated with secondline chemotherapy, the difference was not statistically significant. Our results do not support the proposal that secondline chemotherapy could be effective in patients with MPM.

show abstract

Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience

Cited by 10 publications

References 28 publications

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience

Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma

Secondline Chemotherapy Versus Best Supportive Care in Patient with Malignant Pleural Mesothelioma: A Retrospective Study

Contact Info

Product

Resources

About